参考文献/References:
[1] Vallon V,Thomson SC.Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition[J].Diabetologia,2017,60(2):215-225.DOI:10.1007/s00125-016-4157-3.
[2] Leiter LA,Cefalu WT,de Bruin TW,et al.Dapagliflozin added to usual care in individuals with type 2 diabetes mellitus with preexisting cardiovascular disease:a 24-week,multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension[J].J Am Geriatr Soc,2014,62(7):1252-1262.DOI:10.1111/jgs.12881.
[3] Riser Taylor S,Harris KB.The clinical efficacy and safety of sodium glucose cotransporter-2 inhibitors in adults with type 2 diabetes mellitus[J].Pharmacotherapy,2013,33(9):984-999.DOI:10.1002/phar.1303. [4] Hediger MA,Johnson RJ,Miyazaki H,et al. Molecular physiology of urate transport[J].Physiology(Bethesda),2005,20:125-133.DOI:10.1152/physiol.00039.2004.
[5] Billiet L,Doaty S,Katz JD,et al.Review of hyperuricemia as new marker for metabolic syndrome[J].ISRN Rheumatol,2014,2014:852954.DOI:10.1155/2014/852954.
[6] Hao Z,Huang X,Shao H,et al.Effects of dapagliflozin on serum uric acid levels in hospitalized type 2 diabetic patients with inadequate glycemic control: a randomized controlled trial[J].Ther Clin Risk Manag,2018,14:2407-2413.DOI:10.2147/TCRM.S186347.
[7] Xu Y,Zhu J,Gao L,et al.Hyperuricemia as an independent predictor of vascular complications and mortality in type 2 diabetes patients: a meta-analysis[J].PLoS One,2013,8(10):e78206.DOI:10.1371/journal.pone.0078206.
[8] Maiuolo J,Oppedisano F,Gratteri S,et al.Regulation of uric acid metabolism and excretion[J].Int J Cardiol,2016,213:8-14.DOI:10.1016/j.ijcard.2015.08.109.
[9] So A,Thorens B.Uric acid transport and disease[J].J Clin Invest,2010,120(6):1791-1799.DOI:10.1172/JCI42344.
[10] Novikov A,Fu Y,Huang W,et al.SGLT2 inhibition and renal urate excretion: role of luminal glucose,GLUT9, and URAT1[J].Am J Physiol Renal Physiol,2019,316(1):F173-F185.DOI:10.1152/ajprenal.00462.2018.
[11] Wright AF,Rudan I,Hastie ND,et al.A 'complexity' of urate transporters[J].Kidney Int,2010,78(5):446-452.DOI:10.1038/ki.2010.206.
[12] Bailey CJ.Uric acid and the cardio-renal effects of SGLT2 inhibitors[J].Diabetes Obes Metab,2019,21(6):1291-1298.DOI:10.1111/dom.13670.
[13] Bobulescu IA,Moe OW.Renal transport of uric acid: evolving concepts and uncertainties[J].Adv Chronic Kidney Dis,2012,19(6):358-371.DOI:10.1053/j.ackd.2012.07.009.
[14] Zhao Y,Xu L,Tian D,et al.Effects of sodium-glucose co-transporter 2(SGLT2)inhibitors on serum uric acid level: a meta-analysis of randomized controlled trials[J].Diabetes Obes Metab,2018,20(2):458-462.DOI:10.1111/dom.13101.
[15] Zinman B,Wanner C,Lachin JM,et al.Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes[J].N Engl J Med,2015,373(22):2117-2128.DOI:10.1056/NEJMoa1504720.
[16] Davies MJ,Trujillo A,Vijapurkar U,et al.Effect of canagliflozin on serum uric acid in patients with type 2 diabetes mellitus[J].Diabetes Obes Metab,2015,17(4):426-429.DOI:10.1111/dom.12439.
[17] Sha S,Polidori D,Heise T,et al. Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus[J].Diabetes Obes Metab,2014,16(11):1087-1095.DOI:10.1111/dom.12322.
[18] List JF,Woo V,Morales E,et al.Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes[J].Diabetes Care,2009,32(4):650-657.DOI:10.2337/dc08-1863.
[19] Bailey CJ,Gross JL,Hennicken D,et al.Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind,placebo-controlled 102-week trial[J].BMC Med,2013,11:43.DOI:10.1186/1741-7015-11-43.
[20] Wilding JP,Norwood P,T'joen C,et al.A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers:applicability of a novel insulin-independent treatment[J].Diabetes Care,2009,32(9):1656-1662.DOI:10.2337/dc09-0517.
[21] Chino Y,Samukawa Y,Sakai S,et al.SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria[J].Biopharm Drug Dispos,2014,35(7):391-404.DOI:10.1002/bdd.1909.
[22] Ouchi M,Oba K,Kaku K,et al.Uric acid lowering in relation to HbA1c reductions with the SGLT2 inhibitor tofogliflozin[J].Diabetes Obes Metab,2018,20(4):1061-1065.DOI:10.1111/dom.13170.
[23] Caulfield MJ,Munroe PB,O'Neill D,et al.SLC2A9 is a high-capacity urate transporter in humans[J].PLoS Med,2008,5(10):e197.DOI:10.1371/journal.pmed.0050197.
[24] Kimura T,Takahashi M,Yan K,et al.Expression of SLC2A9 isoforms in the kidney and their localization in polarize depithelial cells[J].PLoS One,2014,9(1):e84996.DOI:10.1371/journal.pone.0084996.
[25] Lytvyn Y, Sˇkrti M,Yang GK,et al.Glycosuria-mediated urinary uric acid excretion in patients with uncomplicated type 1 diabetes mellitus[J].Am J Physiol Renal Physiol,2015,308(2):F77-F83.DOI:10.1152/ajprenal.00555.2014.
[26] Samukawa Y,Omiya H,Watase H,et al.Substantial effects of luseogliflozin revealed by analyzing responses to postprandial hyperglycemia: post hoc subanalyses of a randomized controlled study[J].Adv Ther,2016,33(7):1215-1230.DOI:10.1007/s12325-016-0350-5.
[27] Muscelli E,Natali A,Bianchi S,et al. Effect of insulin on renal sodium and uric acid handling in essential hypertension[J].Am J Hypertens,1996,9(8):746-752.DOI:10.1016/0895-7061(96)00098-2.
[28] Toyoki D,Shibata S,Kuribayashi-Okuma E,et al.Insulin stimulates uric acid reabsorption via regulating urate transporter 1 and ATP-binding cassette subfamily G member 2[J].Am J Physiol Renal Physiol,2017,313(3):F826-F834.DOI:10.1152/ajprenal.00012.2017.
相似文献/References:
[1]赵紫琴,雒瑢,田凤石,等.替米沙坦对OLETF大鼠皮下和内脏脂肪组织PPARγ表达的影响[J].国际内分泌代谢杂志,2014,(06):365.[doi:10.3760/cma.j.issn.1673-4157.2014.06.002]
Zhao Ziqin*,Luo Rong,Tian Fengshi,et al.Effects of telmisartan on expression of PPARγ in subcutaneous and visceral adipose tissue in OLETF rats[J].International Journal of Endocrinology and Metabolism,2014,(02):365.[doi:10.3760/cma.j.issn.1673-4157.2014.06.002]
[2]姚霜霜,张翼飞,张志国,等.小檗碱改善代谢性疾病的肠道相关机制[J].国际内分泌代谢杂志,2014,(06):386.[doi:10.3760/cma.j.issn.1673-4157.2014.06.007]
Yao Shuangshuang,Zhang Yifei,Zhang Zhiguo,et al.The gut-related mechanisms of berberine in the treatment of metabolic diseases[J].International Journal of Endocrinology and Metabolism,2014,(02):386.[doi:10.3760/cma.j.issn.1673-4157.2014.06.007]
[3]曹萌 韦晓 刘超.自噬与胰岛β细胞功能及2型糖尿病[J].国际内分泌代谢杂志,2015,(01):53.[doi:10.3760/cma.j.issn.1673-4157.2015.01.013]
Cao Meng,Wei Xiao,Liu Chao..Relationship between autophagy and islet β cells function, type 2 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2015,(02):53.[doi:10.3760/cma.j.issn.1673-4157.2015.01.013]
[4]刘艳 田秀标 韩颖.GLP-1受体激动剂呈葡萄糖依赖性刺激胰岛β细胞胰岛素分泌的机制[J].国际内分泌代谢杂志,2015,(01):66.[doi:10.3760/cma.j.issn.1673-4157.2015.01.017]
Liu Yan*,Tian Xiubiao,Han Ying..Mechanism of GLP-1 receptor agonists in the stimulation of insulin secretion of islet β cell in a glucose-dependent manner[J].International Journal of Endocrinology and Metabolism,2015,(02):66.[doi:10.3760/cma.j.issn.1673-4157.2015.01.017]
[5]齐利琴,刘礼斌.GLP-1在2型糖尿病诱发的阿尔茨海默病治疗中的作用[J].国际内分泌代谢杂志,2016,36(01):48.[doi:10.3760/cma.j.issn.1673-4157.2016.01.012]
Qi Liqin,Liu Libin..Effects of GLP-1 in the treatment of Alzheimer's disease induced by type 2 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2016,36(02):48.[doi:10.3760/cma.j.issn.1673-4157.2016.01.012]
[6]梅稳,向光大,卢俊颜,等.GDF11对ApoE-/-糖尿病小鼠内皮依赖性
血管舒张功能的作用[J].国际内分泌代谢杂志,2016,36(02):101.[doi:10.3760/cma.j.issn.1673-4157.2016.02.007]
Mei Wen*,Xiang Guangda,Lu Junyan,et al.Effects of GDF11 on endothelium-dependent vasodiation function of aorta in ApoE-/- diabetic mice[J].International Journal of Endocrinology and Metabolism,2016,36(02):101.[doi:10.3760/cma.j.issn.1673-4157.2016.02.007]
[7]殷俏,张云良,郭淑芹,等.视黄醇结合蛋白4、超敏C反应蛋白
与糖尿病视网膜病变的关系[J].国际内分泌代谢杂志,2016,36(03):149.[doi:10.3760/cma.j.issn.1673-4157.2016.03.02]
Yin Qiao,Zhang Yunliang,Guo Shuqin,et al.Relationship of retinol binding protein 4 and high sensitive C-reactive protein with diabetic retinopathy[J].International Journal of Endocrinology and Metabolism,2016,36(02):149.[doi:10.3760/cma.j.issn.1673-4157.2016.03.02]
[8]王涛,张洁,祁范范,等.不同糖耐量人群血清25(OH)D3水平
及与胰岛β细胞功能的关系[J].国际内分泌代谢杂志,2016,36(04):226.[doi:10.3760/cma.j.issn.1673-4157.2016.04.04]
Wang Tao*,Zhang Jie,Qi Fanfan,et al.Relationship between serum 25(OH)D3 level and islet β cell function in individuals with different glucose tolerance[J].International Journal of Endocrinology and Metabolism,2016,36(02):226.[doi:10.3760/cma.j.issn.1673-4157.2016.04.04]
[9]陈双双,王楚媛,孔令芳.铬与2型糖尿病[J].国际内分泌代谢杂志,2016,36(04):272.[doi:10.3760/cma.j.issn.1673-4157.2016.04.13]
Chen Shuangshuang,Wang Chuyuan,Kong Lingfang.Chromium and type 2 diabetes[J].International Journal of Endocrinology and Metabolism,2016,36(02):272.[doi:10.3760/cma.j.issn.1673-4157.2016.04.13]
[10]涂萍,许婷,段鹏,等.25-羟维生素D3补充对绝经后2型糖尿病
患者胰岛素敏感性及血糖控制的影响[J].国际内分泌代谢杂志,2016,36(05):299.[doi:10.3760/cma.j.issn.1673-4157.2016.05.04]
Tu Ping,Xu Ting,Duan Peng,et al.Influence of 25-hydroxyvitamin D3 supplement on insulin sensitivity and glucose control in postmenopausal patients with type 2 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2016,36(02):299.[doi:10.3760/cma.j.issn.1673-4157.2016.05.04]